Cibinetide, ARA-290 and pyroglutamate helix-B surface peptide refer to a defined 11-residue peptide. Exact sequence and terminal chemistry matter more than a familiar research code.
Evidence at a glance
- PubChem lists cibinetide as an 11-mer with molecular formula C51H84N16O21 and molecular weight 1257.3 g/mol.
- The sequence begins with pyroglutamate and is recorded as pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser.
- The phrase “erythropoietin-derived” describes design origin; it does not mean the material is erythropoietin.
Identity record
The N-terminal pyroglutamate is an identity-defining modification. A linear sequence written with an ordinary glutamine or glutamate at that position is not the same record.
Analytical and evidence boundary
Mass spectrometry can support identity, while chromatography can separate major components. Neither alone establishes absolute peptide content, sterility, endotoxin status or suitability for a biological system.
Human study language should name the actual population and endpoint. “Investigated in sarcoidosis-associated small-fiber neuropathy” is accurate; “repairs nerves” overstates a small and mixed clinical record.
Editorial rule
State the exact material, form, model or population and endpoint supported by the cited record. Do not convert mechanistic plausibility, an animal result, a finished-drug label or an analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Randomized ARA-290 sarcoidosis-neuropathy pilotPrimary exploratory trial; PMID 23168581.
- Phase 2 clinical trial of cibinetide for diabetic macular edemaClinical Ophthalmology. 2020. PMID 32674280.
- PubChem Cibinetide recordSequence, synonyms, formula and mass; CID 91810664.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
